Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.

Clinical pharmacology : advances and applications

Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D.
PMID: 29042821
Clin Pharmacol. 2017 Oct 03;9:101-111. doi: 10.2147/CPAA.S138414. eCollection 2017.

Biopharmaceuticals directed against tumor necrosis factor-alpha, integrins, interleukins, interferons and their receptors have become key agents for the management of inflammatory diseases in the fields of gastroenterology, rheumatology, dermatology and neurology. However, response to these treatments is far from...

Cite
Dreesen E, Bossuyt P, Mulleman D, et al. Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Clin Pharmacol. 2017;9:101-111doi: 10.2147/CPAA.S138414.
Dreesen, E., Bossuyt, P., Mulleman, D., Gils, A., & Pascual-Salcedo, D. (2017). Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Clinical pharmacology : advances and applications, 9101-111. https://doi.org/10.2147/CPAA.S138414
Dreesen, Erwin, et al. "Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases." Clinical pharmacology : advances and applications vol. 9 (2017): 101-111. doi: https://doi.org/10.2147/CPAA.S138414
Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D. Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Clin Pharmacol. 2017 Oct 03;9:101-111. doi: 10.2147/CPAA.S138414. eCollection 2017. PMID: 29042821; PMCID: PMC5633318.
Copy Download .nbib Format: NLM
Early monitoring of infliximab serum trough levels predicts long-term therapy failure in patients with axial spondyloarthritis.

Scandinavian journal of rheumatology

Martínez-Feito A, Navarro-Compán V, Hernández-Breijo B, Olariaga-Mérida E, Peiteado D, Villalba A, Nuño L, Monjo I, Diego C, Pascual-Salcedo D, Nozal P, Balsa A, Plasencia-Rodríguez C.
PMID: 34182885
Scand J Rheumatol. 2021 Jun 29;1-8. doi: 10.1080/03009742.2021.1914430. Epub 2021 Jun 29.

No abstract available.

Cite
Martínez-Feito A, Navarro-Compán V, Hernández-Breijo B, et al. Early monitoring of infliximab serum trough levels predicts long-term therapy failure in patients with axial spondyloarthritis. Scand J Rheumatol. 2021;1-8doi: 10.1080/03009742.2021.1914430.
Martínez-Feito, A., Navarro-Compán, V., Hernández-Breijo, B., Olariaga-Mérida, E., Peiteado, D., Villalba, A., Nuño, L., Monjo, I., Diego, C., Pascual-Salcedo, D., Nozal, P., Balsa, A., & Plasencia-Rodríguez, C. (2021). Early monitoring of infliximab serum trough levels predicts long-term therapy failure in patients with axial spondyloarthritis. Scandinavian journal of rheumatology, 1-8. https://doi.org/10.1080/03009742.2021.1914430
Martínez-Feito, A, et al. "Early monitoring of infliximab serum trough levels predicts long-term therapy failure in patients with axial spondyloarthritis." Scandinavian journal of rheumatology vol. (2021): 1-8. doi: https://doi.org/10.1080/03009742.2021.1914430
Martínez-Feito A, Navarro-Compán V, Hernández-Breijo B, Olariaga-Mérida E, Peiteado D, Villalba A, Nuño L, Monjo I, Diego C, Pascual-Salcedo D, Nozal P, Balsa A, Plasencia-Rodríguez C. Early monitoring of infliximab serum trough levels predicts long-term therapy failure in patients with axial spondyloarthritis. Scand J Rheumatol. 2021 Jun 29;1-8. doi: 10.1080/03009742.2021.1914430. Epub 2021 Jun 29. PMID: 34182885.
Copy Download .nbib Format: NLM
Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis.

Frontiers in medicine

Hernández-Breijo B, Plasencia-Rodríguez C, Navarro-Compán V, García-Hoz C, Nieto-Gañán I, Sobrino C, Bachiller-Corral J, Díaz-Almirón M, Martínez-Feito A, Jurado T, Lapuente-Suanzes P, Bonilla G, Pijoán-Moratalla C, Roy G, Vázquez-Díaz M, Balsa A, Villar LM, Pascual-Salcedo D, Rodríguez-Martín E.
PMID: 34222289
Front Med (Lausanne). 2021 Jun 17;8:683990. doi: 10.3389/fmed.2021.683990. eCollection 2021.

Biological therapies, such as TNF inhibitors (TNFi), are increasing remission (REM) rates in rheumatoid arthritis (RA) patients, although these are still limited. The aim of our study was to analyze changes in the profile of peripheral blood mononuclear cells...

Cite
Hernández-Breijo B, Plasencia-Rodríguez C, Navarro-Compán V, et al. Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis. Front Med (Lausanne). 2021;8:683990doi: 10.3389/fmed.2021.683990.
Hernández-Breijo, B., Plasencia-Rodríguez, C., Navarro-Compán, V., García-Hoz, C., Nieto-Gañán, I., Sobrino, C., Bachiller-Corral, J., Díaz-Almirón, M., Martínez-Feito, A., Jurado, T., Lapuente-Suanzes, P., Bonilla, G., Pijoán-Moratalla, C., Roy, G., Vázquez-Díaz, M., Balsa, A., Villar, L. M., Pascual-Salcedo, D., & Rodríguez-Martín, E. (2021). Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis. Frontiers in medicine, 8683990. https://doi.org/10.3389/fmed.2021.683990
Hernández-Breijo, Borja, et al. "Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis." Frontiers in medicine vol. 8 (2021): 683990. doi: https://doi.org/10.3389/fmed.2021.683990
Hernández-Breijo B, Plasencia-Rodríguez C, Navarro-Compán V, García-Hoz C, Nieto-Gañán I, Sobrino C, Bachiller-Corral J, Díaz-Almirón M, Martínez-Feito A, Jurado T, Lapuente-Suanzes P, Bonilla G, Pijoán-Moratalla C, Roy G, Vázquez-Díaz M, Balsa A, Villar LM, Pascual-Salcedo D, Rodríguez-Martín E. Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis. Front Med (Lausanne). 2021 Jun 17;8:683990. doi: 10.3389/fmed.2021.683990. eCollection 2021. PMID: 34222289; PMCID: PMC8245775.
Copy Download .nbib Format: NLM
Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions.

Frontiers in medicine

Plasencia C, Jurado T, Villalba A, Peitedado D, Casla MT, Nuño L, Bonilla MG, Martínez-Feito A, Martín-Mola E, Pascual-Salcedo D, Balsa A.
PMID: 26501060
Front Med (Lausanne). 2015 Oct 08;2:71. doi: 10.3389/fmed.2015.00071. eCollection 2015.

BACKGROUND: Evidence supporting treatment intensification in rheumatoid arthritis (RA) is limited and controversial. We explored outcomes of infliximab dose increases and accounted for pre-existing trough levels in patients with active RA.METHODS: This study was a retrospective study of 42...

Cite
Plasencia C, Jurado T, Villalba A, et al. Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions. Front Med (Lausanne). 2015;2:71doi: 10.3389/fmed.2015.00071.
Plasencia, C., Jurado, T., Villalba, A., Peitedado, D., Casla, M. T., Nuño, L., Bonilla, M. G., Martínez-Feito, A., Martín-Mola, E., Pascual-Salcedo, D., & Balsa, A. (2015). Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions. Frontiers in medicine, 271. https://doi.org/10.3389/fmed.2015.00071
Plasencia, Chamaida, et al. "Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions." Frontiers in medicine vol. 2 (2015): 71. doi: https://doi.org/10.3389/fmed.2015.00071
Plasencia C, Jurado T, Villalba A, Peitedado D, Casla MT, Nuño L, Bonilla MG, Martínez-Feito A, Martín-Mola E, Pascual-Salcedo D, Balsa A. Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions. Front Med (Lausanne). 2015 Oct 08;2:71. doi: 10.3389/fmed.2015.00071. eCollection 2015. PMID: 26501060; PMCID: PMC4597116.
Copy Download .nbib Format: NLM
Predictive Value of Serum Infliximab Levels at Induction Phase in Rheumatoid Arthritis Patients.

The open rheumatology journal

Teresa J, Chamaida PR, Ana MF, Victoria NC, Theo R, Annick V, Karien B, Eva-María O, Cristina D, Alejandro V, Diana P, Laura N, Maria-Gema B, Alejandro B, Dora PS.
PMID: 28761564
Open Rheumatol J. 2017 Jun 29;11:75-87. doi: 10.2174/1874312901711010075. eCollection 2017.

BACKGROUND: The Infliximab, has proven effective in treating rheumatoid arthritis (RA). A good clinical response is usually associated with high serum drug levels. Development of antibodies toward Infliximab (ATI) can increase drug clearance, leading to treatment failure.AIMS: To analyze...

Cite
Teresa J, Chamaida PR, Ana MF, et al. Predictive Value of Serum Infliximab Levels at Induction Phase in Rheumatoid Arthritis Patients. Open Rheumatol J. 2017;11:75-87doi: 10.2174/1874312901711010075.
Teresa, J., Chamaida, P. R., Ana, M. F., Victoria, N. C., Theo, R., Annick, V., Karien, B., Eva-María, O., Cristina, D., Alejandro, V., Diana, P., Laura, N., Maria-Gema, B., Alejandro, B., & Dora, P. S. (2017). Predictive Value of Serum Infliximab Levels at Induction Phase in Rheumatoid Arthritis Patients. The open rheumatology journal, 1175-87. https://doi.org/10.2174/1874312901711010075
Teresa, Jurado, et al. "Predictive Value of Serum Infliximab Levels at Induction Phase in Rheumatoid Arthritis Patients." The open rheumatology journal vol. 11 (2017): 75-87. doi: https://doi.org/10.2174/1874312901711010075
Teresa J, Chamaida PR, Ana MF, Victoria NC, Theo R, Annick V, Karien B, Eva-María O, Cristina D, Alejandro V, Diana P, Laura N, Maria-Gema B, Alejandro B, Dora PS. Predictive Value of Serum Infliximab Levels at Induction Phase in Rheumatoid Arthritis Patients. Open Rheumatol J. 2017 Jun 29;11:75-87. doi: 10.2174/1874312901711010075. eCollection 2017. PMID: 28761564; PMCID: PMC5510569.
Copy Download .nbib Format: NLM
Methotrexate Reduces the Probability of Discontinuation of TNF Inhibitors in Seropositive Patients With Rheumatoid Arthritis. A Real-World Data Analysis.

Frontiers in medicine

Hernández-Breijo B, Brenis CM, Plasencia-Rodríguez C, Martínez-Feito A, Novella-Navarro M, Pascual-Salcedo D, Balsa A.
PMID: 34268325
Front Med (Lausanne). 2021 Jun 29;8:692557. doi: 10.3389/fmed.2021.692557. eCollection 2021.

Tumor necrosis factor inhibitors (TNFi) are widely used for the treatment of patients with rheumatoid arthritis (RA), however a considerable percentage of patients discontinued the therapy. The aim of this study is to explore real-world TNFi survival, stratified for...

Cite
Hernández-Breijo B, Brenis CM, Plasencia-Rodríguez C, et al. Methotrexate Reduces the Probability of Discontinuation of TNF Inhibitors in Seropositive Patients With Rheumatoid Arthritis. A Real-World Data Analysis. Front Med (Lausanne). 2021;8:692557doi: 10.3389/fmed.2021.692557.
Hernández-Breijo, B., Brenis, C. M., Plasencia-Rodríguez, C., Martínez-Feito, A., Novella-Navarro, M., Pascual-Salcedo, D., & Balsa, A. (2021). Methotrexate Reduces the Probability of Discontinuation of TNF Inhibitors in Seropositive Patients With Rheumatoid Arthritis. A Real-World Data Analysis. Frontiers in medicine, 8692557. https://doi.org/10.3389/fmed.2021.692557
Hernández-Breijo, Borja, et al. "Methotrexate Reduces the Probability of Discontinuation of TNF Inhibitors in Seropositive Patients With Rheumatoid Arthritis. A Real-World Data Analysis." Frontiers in medicine vol. 8 (2021): 692557. doi: https://doi.org/10.3389/fmed.2021.692557
Hernández-Breijo B, Brenis CM, Plasencia-Rodríguez C, Martínez-Feito A, Novella-Navarro M, Pascual-Salcedo D, Balsa A. Methotrexate Reduces the Probability of Discontinuation of TNF Inhibitors in Seropositive Patients With Rheumatoid Arthritis. A Real-World Data Analysis. Front Med (Lausanne). 2021 Jun 29;8:692557. doi: 10.3389/fmed.2021.692557. eCollection 2021. PMID: 34268325; PMCID: PMC8275858.
Copy Download .nbib Format: NLM
Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses.

Frontiers in neurology

Serra López-Matencio JM, Pérez García Y, Meca-Lallana V, Juárez-Sánchez R, Ursa A, Vega-Piris L, Pascual-Salcedo D, de Vries A, Rispens T, Muñoz-Calleja C.
PMID: 34690914
Front Neurol. 2021 Oct 07;12:716548. doi: 10.3389/fneur.2021.716548. eCollection 2021.

No abstract available.

Cite
Serra López-Matencio JM, Pérez García Y, Meca-Lallana V, et al. Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses. Front Neurol. 2021;12:716548doi: 10.3389/fneur.2021.716548.
Serra López-Matencio, J. M., Pérez García, Y., Meca-Lallana, V., Juárez-Sánchez, R., Ursa, A., Vega-Piris, L., Pascual-Salcedo, D., de Vries, A., Rispens, T., & Muñoz-Calleja, C. (2021). Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses. Frontiers in neurology, 12716548. https://doi.org/10.3389/fneur.2021.716548
Serra López-Matencio, Jose M, et al. "Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses." Frontiers in neurology vol. 12 (2021): 716548. doi: https://doi.org/10.3389/fneur.2021.716548
Serra López-Matencio JM, Pérez García Y, Meca-Lallana V, Juárez-Sánchez R, Ursa A, Vega-Piris L, Pascual-Salcedo D, de Vries A, Rispens T, Muñoz-Calleja C. Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses. Front Neurol. 2021 Oct 07;12:716548. doi: 10.3389/fneur.2021.716548. eCollection 2021. PMID: 34690914; PMCID: PMC8529019.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries